KEMPHARM (KMPH) Covered Calls

You can sell covered calls on KEMPHARM to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for KMPH (prices last updated Fri 4:16 PM ET):

KEMPHARM (KMPH) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.51 +0.03 2.43 2.68 709K - 0.0B
Covered Calls For KEMPHARM (KMPH)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 2.5 0.00 2.68 -6.7% -84.3%
Dec 21 2.5 0.00 2.68 -6.7% -38.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company was founded in 2006 and is headquartered in Coralville, Iowa.